A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results

Rouëssé, Jacques; Lande, B. De La; Bertheault-Cvitkovic, F.; Serin, D.; Graic, Y.; Combe, M.; Leduc, Bernard; Lucas, Virginie; Demange, L.; Nguyen, Tan Dat; Castéra, D.; Krzisch, C.; Villet, R.; Mouret-Fourme, Emmanuelle; Garbay, J. R.; Noguès, Catherine

doi:10.1016/j.ijrobp.2005.10.011

Cited by 69 publications

(46 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From among the 323 patients treated at René Huguenin Cancer Center, 97 tumor samples were immediately stored in liquid nitrogen until RNA extraction. The trial compared concomitant adjuvant chemoradiotherapy with sequential chemotherapy plus radiotherapy and was described previously (19). Our institutional review board approved the acquisition, analysis, and reporting of the patients' data.…”

Section: Patients and Tumor Samplesmentioning

confidence: 99%

DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients

Scodan

Cizeron-Clairac

Fourme

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Section: Patients and Tumor Samplesmentioning

confidence: 99%

DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients

Scodan

Cizeron-Clairac

Fourme

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

“…Récemment, deux essais randomisés de phase III [39,40] comparant une chimioradiothérapie séquentielle et une chimioradiothérapie concomitante ont été publiés. L'étude ayant inclus un nombre plus important de patientes [40] ainsi qu'une seconde étude française (ARCOSEIN) [41] ont montré chez les patientes ayant un envahissement ganglionnaire axillaire un taux de contrôle locorégional significativement meilleur dans le bras chimioradiothérapie concomitante, mais au prix d'une toxicité tardive majorée.…”

Section: Association De La Radiothérapie à La Chimiothérapieunclassified

Radiothérapie et associations thérapeutiques dans le cancer du sein : actualités et innovations en situation adjuvante

Belkacémi

Gligorov²,

Chauvet

et al. 2010

Journal de Gynécologie Obstétrique et Biologie de la Reproducti

View full text Add to dashboard Cite

“…Concomitant radiochemotherapy, while having proven very effective for many tumours, [19][20][21] with better local control and improved survival, has been hardly assessed for breast cancer, [22][23][24] and very rarely in a pre-operative setting. [25][26][27][28] Moreover, several authors have recently demonstrated that lowdose fractionated radiotherapy (LD-FRT) is able to enhance the effectiveness of multiple chemotherapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer

Santis

Nardone

Diletto

et al. 2016

BJR

View full text Add to dashboard Cite

Objective: After breast conservative surgery (BCS) and whole-breast radiotherapy (WBRT), the use of boost irradiation is recommended especially in patients at high risk. However, the standard technique and the definition of the boost volume have not been well defined. Methods: We retrospectively compared an anticipated pre-operative photon boost on the tumour, administered with low-dose fractionated radiotherapy, and neoadjuvant chemotherapy with two different sequential boost techniques, administered after BCS and standard adjuvant WBRT: (1) a standard photon beam (2) and an electron beam technique on the tumour bed of the same patients. The plans were analyzed for the dosimetric coverage of the CT-delineated irradiated volume. The minimal dose received by 95% of the target volume (D 95 ), the minimal dose received by 90% of the target volume (D 90 ) and geographic misses were evaluated. Results: 15 patients were evaluated. The sequential photon and electron boost techniques resulted in inferior target volume coverage compared with the anticipated boost technique, with a median D 95 of 96.3% (range 94.7-99.6%) and 0.8% (range 0-30%) and a median D 90 of 99.1% (range 90.2-100%) and 54.7% (range 0-84.8%), respectively. We observed a geographic miss in 26.6% of sequential electron plans. The results of the anticipated boost technique were better: 99.4% (range 96.5-100%) and 97.1% (range 86.2-99%) for median D 90 and median D 95 , respectively, and no geographic miss was observed. We observed a dose reduction to the heart, with left-sided breast irradiation, using the anticipated pre-operative boost technique, when analyzed for all dose-volume parameters. When compared with the sequential electron plans, the pre-operative photon technique showed a higher median ipsilateral lung D max . Conclusion: Our data show that an anticipated preoperative photon boost results in a better coverage with respect to the standard sequential boost while also saving the organs at risk and consequently fewer side effects. Advances in knowledge: This is the first dosimetric study that evaluated the association between an anticipated boost and neoadjuvant chemotherapy treatment.

show abstract

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results

Cited by 69 publications

References 38 publications

DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients

DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients

Radiothérapie et associations thérapeutiques dans le cancer du sein : actualités et innovations en situation adjuvante

Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer

Contact Info

Product

Resources

About